TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18690005

Group type: EXPERIMENTAL
Intervention: Prenatal screening offered
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prenatal screening offered (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decliners of the screening test
Number of subjects: 0
Study: 15632339

Group type: EXPERIMENTAL
Intervention: Urinary PIGF concentrations in women with preeclampsia
Number of subjects: 240

Group type: COMPARATOR
Intervention: Urinary PIGF concentrations in normotensive controls
Number of subjects: 240

Group type: COMPARATOR
Intervention: Lowest quartile of control PIGF concentrations (<118 pg/mL)
Number of subjects: 240
Study: 12745724

Group type: EXPERIMENTAL
Intervention: Oral ephedrine 50 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Only premedication (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Supplemental ephedrine (3 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Atropine (0.5 mg)
Number of subjects: 60
Study: 11206014

Group type: EXPERIMENTAL
Intervention: Pharmacologic therapy to passivate plaque for at least 24 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors
Number of subjects: 0
Study: 8645662

Group type: EXPERIMENTAL
Intervention: Soluble ibuprofen 200 mg
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Soluble ibuprofen 400 mg
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Soluble ibuprofen 600 mg
Number of subjects: 148

Group type: COMPARATOR
Intervention: Ibuprofen tablets 200 mg
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Ibuprofen tablets 400 mg
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Ibuprofen tablets 600 mg
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 1346564

Group type: EXPERIMENTAL
Intervention: Clonidine, 0.075 mg orally, at baseline and after 2 hours if heart rate did not decrease by at least 20%
Number of subjects: 18

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Clonidine and Control
Number of subjects: 18
Study: 6302650

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Cimetidine (200 mg three times daily and 400 mg at night)
Number of subjects: 106
Study: 31168411

Group type: EXPERIMENTAL
Intervention: Fosdagrocorat 10 mg
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Fosdagrocorat 15 mg
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Fosdagrocorat 1 mg, 5 mg, 10 mg
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Fosdagrocorat 1 mg, 5 mg, 10 mg, 15 mg
Number of subjects: 323

Group type: COMPARATOR
Intervention: Prednisone 10 mg
Number of subjects: 323

Group type: COMPARATOR
Intervention: Prednisone 5 mg
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study: 29541895

Group type: EXPERIMENTAL
Intervention: Dual observer group (experienced nurse participation)
Number of subjects: 587

Group type: COMPARATOR
Intervention: Single observer group (experienced colonoscopist alone)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 587
Study: 26531829

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nitrate
Number of subjects: 52
Study: 23868159

Group type: EXPERIMENTAL
Intervention: Operators' evaluation of angiographic appearance immediately after embolization
Number of subjects: 434

Group type: COMPARATOR
Intervention: Core laboratory evaluation of angiographic appearance immediately after embolization
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Operators' evaluation of angiographic appearance at follow-up
Number of subjects: 434

Group type: COMPARATOR
Intervention: Core laboratory evaluation of angiographic appearance at follow-up
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Operators' overall evaluation of unfavorable angiographic appearance
Number of subjects: 434

Group type: COMPARATOR
Intervention: Core laboratory's overall evaluation of unfavorable angiographic appearance
Number of subjects: 434
Study: 22365462

Group type: EXPERIMENTAL
Intervention: Cool Teens program (12-week computerized cognitive-behavioral therapy program for anxiety management)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Wait list (control group)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cool Teens program
Number of subjects: 43
Study: 19481279

Group type: EXPERIMENTAL
Intervention: Simvastatin (low dose: 5 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Simvastatin (moderate dose: 10 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no statin)
Number of subjects: 28
Study: 18657653

Group type: EXPERIMENTAL
Intervention: Electrocardiographic spontaneous reperfusion (ECG SR)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Angiographic spontaneous reperfusion (Angiographic SR)
Number of subjects: 585
Study: 16177674

Group type: EXPERIMENTAL
Intervention: Rhythm control (Amiodarone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rate control (Digoxin and beta-blocker)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-pharmacologic approaches (catheter-based techniques)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AV node ablation and pacemaker implantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term oral anticoagulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implantation of a defibrillator
Number of subjects: 0
Study: 16388222

Group type: EXPERIMENTAL
Intervention: Local anaesthetic with dexamethasone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Local anaesthetic without dexamethasone
Number of subjects: 40
Study: 10885210

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8843283

Group type: EXPERIMENTAL
Intervention: Crystalline formulation of erythromycin ethylsuccinate (CEE) at 1,000 mg every 12 h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amorphous formulation of erythromycin ethylsuccinate (AEE) at 500 mg every 12 h
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1503486

Group type: EXPERIMENTAL
Intervention: Cefpiramide + amikacin (CPM + AMK)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Piperacillin + amikacin (PIPC + AMK)
Number of subjects: 141
Study: 6233398

Group type: EXPERIMENTAL
Intervention: 1,000 mg intramuscular (IM) MPA (high dose) daily for four weeks
Number of subjects: 210

Group type: COMPARATOR
Intervention: 500 mg IM MPA (low dose) twice weekly for four weeks
Number of subjects: 210
Study: 31176466

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test adapted to children
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 81
Study: 30202836

Group type: EXPERIMENTAL
Intervention: Brånemark
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Swede-Vent
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Screw-Vent
Number of subjects: 58
Study: 27640987

Group type: EXPERIMENTAL
Intervention: Antihypertensive medications
Number of subjects: 2299

Group type: EXPERIMENTAL
Intervention: Low BP (systolic BP<120 mmHg, diastolic BP <70 mmHg)
Number of subjects: 2299

Group type: EXPERIMENTAL
Intervention: Baseline characteristics
Number of subjects: 2299
Study: 24272917

Group type: EXPERIMENTAL
Intervention: Romosozumab 1 mg/kg Q2W
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Romosozumab 2 mg/kg Q2W
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Romosozumab 2 mg/kg Q4W
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Romosozumab 3 mg/kg Q4W
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 22342408

Group type: EXPERIMENTAL
Intervention: Narrow band imaging (NBI) cystoscopy associated with bipolar plasma vaporization (BPV)
Number of subjects: 220

Group type: COMPARATOR
Intervention: White light cystoscopy (WLC) and monopolar transurethral resection of bladder tumors (TURBT)
Number of subjects: 220
Study: 20039450

Group type: EXPERIMENTAL
Intervention: Standing position (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Supine position (Group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Right supine position (Group C)
Number of subjects: 90
Study: 18574390

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 20 mg tid for 3 months (n = 19)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo for 3 months (n = 15)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 15757595

Group type: EXPERIMENTAL
Intervention: Bare-metal stent
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent
Number of subjects: 1307
Study: 12472925

Group type: COMPARATOR
Intervention: Patient with coronary artery disease (CAD)
Number of subjects: 1640

Group type: EXPERIMENTAL
Intervention: Patient with PAD
Number of subjects: 1640

Group type: COMPARATOR
Intervention: Patient with no clinically evident atherosclerosis (no disease)
Number of subjects: 1640

Group type: COMPARATOR
Intervention: Patient with CAD
Number of subjects: 1640

Group type: EXPERIMENTAL
Intervention: Cardiologists
Number of subjects: 1640
Study: 10084567

Group type: EXPERIMENTAL
Intervention: 40 mg isoflavones from red clover
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 80 mg isoflavones from red clover
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: COMPARATOR
Intervention: Continuous placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Plasma lipids
Number of subjects: 17
Study: 7778179

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Theophylline (600 mg/day in 2 doses)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 28
Study: 2190460

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate, 20 mg 3 times daily
Number of subjects: 28
Study: 358755

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) 200 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) 400 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) 600 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ)
Number of subjects: 44
Study: 31491792

Group type: EXPERIMENTAL
Intervention: Advancing the Standard (ATS) mechanical valve
Number of subjects: 90

Group type: COMPARATOR
Intervention: St. Jude Medical (SJM) mechanical valve
Number of subjects: 90

Group type: COMPARATOR
Intervention: Carbomedics (CM) mechanical valve
Number of subjects: 90
Study: 31881823

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 264
Study: 28072709

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) - bolus dose of 30 mg/kg i.v, maintenance dosage of 2 mg/kg/h
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA)
Number of subjects: 100
Study: 26429075

Group type: EXPERIMENTAL
Intervention: SI! Program intervention
Number of subjects: 2062

Group type: EXPERIMENTAL
Intervention: SI! Program intervention for 2 years
Number of subjects: 2062

Group type: EXPERIMENTAL
Intervention: SI! Program intervention for 1 year
Number of subjects: 2062

Group type: COMPARATOR
Intervention: Usual curriculum (control group)
Number of subjects: 2062
Study: 24220342

Group type: EXPERIMENTAL
Intervention: Community practice site (intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospital site (usual care)
Number of subjects: 0
Study: 21142377

Group type: EXPERIMENTAL
Intervention: Stronger prevention focus (measured as a chronic disposition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stronger prevention focus (experimentally induced as a temporary state)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concerns about normativeness of managing behavior
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concerns about effectiveness of managing behavior
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Survey of superior-subordinate dyads
Number of subjects: 0
Study: 18086165

Group type: EXPERIMENTAL
Intervention: Sildenafil (25, 50, or 100 mg)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study: 17063108

Group type: EXPERIMENTAL
Intervention: Sedation with intravenous midazolam
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Topical pharyngeal anesthesia with lidocaine throat spray
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo sedation and placebo throat spray
Number of subjects: 252

Group type: COMPARATOR
Intervention: No intravenous cannula nor throat spray (control group)
Number of subjects: 252
Study: 12952691

Group type: EXPERIMENTAL
Intervention: Virtual visits via analogue video-phones, 2 visits per week
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Virtual visits via analogue video-phones
Number of subjects: 10
Study: 11200803

Group type: EXPERIMENTAL
Intervention: Migraine patients (parents and children)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Familial influences
Number of subjects: 40
Study: 9385861

Group type: EXPERIMENTAL
Intervention: Dry meals (normal diet but no water from 1 hour before meals to 1 hour after meals) for one year
Number of subjects: 220

Group type: COMPARATOR
Intervention: Ranitidine 150 mg bd for 3 months
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Dry meals
Number of subjects: 220
Study: 7974316

Group type: EXPERIMENTAL
Intervention: Inspiratory pressure support (IPS) with mean airway pressure 12-15 cm H2O
Number of subjects: 8

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP) 6 cm H2O
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oxygen at 2 l/min via a mask
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control walk using a sham circuit (breathing air via an oxygen mask at 2 l/min from an unlabelled cylinder)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Baseline walk (walking freely on the treadmill)
Number of subjects: 8
Study: 2645086

Group type: EXPERIMENTAL
Intervention: Active involvement of staff only
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Active involvement of residents only
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Active involvement of both residents and staff
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 201
Study: 1162529

Group type: EXPERIMENTAL
Intervention: Aerosol administration of fenoterol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous infusion of fenoterol
Number of subjects: 30
Study: 31931025

Group type: EXPERIMENTAL
Intervention: Piezoelectric scaler (Tigon+®) with warmed water irrigation (approx 36 °C)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Piezoelectric scaler (Tigon+®) with room temperature irrigation (approx 20 °C)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Magnetostrictive scaler (Cavitron Select SPS 30K®) with room temperature irrigation (approx 20 °C)
Number of subjects: 140
Study: 30741567

Group type: EXPERIMENTAL
Intervention: Crocus sativus (saffron) 20-30 mg/d (20 mg/d for <30 kg and 30 mg/d for >30 kg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Methylphenidate (MPH) 20-30 mg/d (20 mg/d for <30 kg and 30 mg/d for >30 kg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Crocus sativus (saffron)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Methylphenidate (MPH)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Crocus sativus (saffron) and Methylphenidate (MPH)
Number of subjects: 54
Study: 28727160

Group type: EXPERIMENTAL
Intervention: Zinc acetate and chlorhexidine diacetate mouth rinse (Zn/CHX)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo mouth rinse
Number of subjects: 46
Study: 24754798

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.25%) infiltration into the surgical wound (Group LA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No infiltration (Group No LA)
Number of subjects: 90
Study: 23630039

Group type: EXPERIMENTAL
Intervention: Beta-alanine (80 mg·kg‐1BM·day‐1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 21212771

Group type: EXPERIMENTAL
Intervention: Intervention group (6 face-to-face sessions, TV locking device, home-based activities)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 19743907

Group type: EXPERIMENTAL
Intervention: Intravesical pentosan polysulfate sodium
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pain and nocturia
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Being currently unmarried
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Unemployed, currently unmarried, obese, never pregnant, and ever use of oral contraceptive
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Symptom severity
Number of subjects: 41
Study: 17173716

Group type: EXPERIMENTAL
Intervention: Motivational tobacco intervention (MTI)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Brief advice or care as usual
Number of subjects: 75
Study: 15812967

Group type: EXPERIMENTAL
Intervention: NIH funded trials (n = 52)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Other trials (not NIH funded)
Number of subjects: 280
Study: 11174337

Group type: EXPERIMENTAL
Intervention: Low-dose ramipril (0.625 mg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Full-dose ramipril (10 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: All patients
Number of subjects: 64
Study: 8883014

Group type: EXPERIMENTAL
Intervention: CUP haemodialysis
Number of subjects: 10

Group type: COMPARATOR
Intervention: PAN haemodialysis
Number of subjects: 10
Study: 1424428

Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3890604

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine (standard analgesic)
Number of subjects: 60
Study: 30170533

Group type: EXPERIMENTAL
Intervention: Oral pills
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Vaginal gels
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Monthly product use
Number of subjects: 271
Study: 29504386

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 32
Study: 26872219

Group type: EXPERIMENTAL
Intervention: Misoprostol treatment by midwives
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Misoprostol treatment by physicians
Number of subjects: 1010
Study: 25060825

Group type: EXPERIMENTAL
Intervention: Preoperative short-term radiotherapy (PRT) + Total mesorectal excision (TME)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Total mesorectal excision (TME)
Number of subjects: 606
Study: 23225854

Group type: EXPERIMENTAL
Intervention: Intranasal administration of borneol (30.0 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of borneol (30.0 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous administration of borneol (30.0 mg/kg)
Number of subjects: 0
Study: 18801829

Group type: EXPERIMENTAL
Intervention: Intranasally administered oxytocin (24 UI)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 17603306

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 0
Study: 16035378

Group type: EXPERIMENTAL
Intervention: Amoxicillin 875 mg tablets (test formulation)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Amoxil BD 875 mg tablets (reference formulation)
Number of subjects: 26
Study: 11753007

Group type: EXPERIMENTAL
Intervention: 40 mg intravenous parecoxib
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9696517

Group type: EXPERIMENTAL
Intervention: Amisulpride 400 mg/day
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Amisulpride 800 mg/day
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Amisulpride 1200 mg/day
Number of subjects: 319

Group type: COMPARATOR
Intervention: Amisulpride 100 mg/day
Number of subjects: 319

Group type: COMPARATOR
Intervention: Haloperidol 16 mg/day
Number of subjects: 319
Study: 7654731

Group type: EXPERIMENTAL
Intervention: Lovastatin (10 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 18
Study: 2127139

Group type: EXPERIMENTAL
Intervention: n-3 PUFA-rich fish oil diet (2 g/day)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: n-3 PUFA-rich fish oil diet (6 g/day)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Reduction diet (combined with fish oil)
Number of subjects: 125

Group type: COMPARATOR
Intervention: n-6 PUFA
Number of subjects: 125
Study: 371629

Group type: EXPERIMENTAL
Intervention: Aspirin (3904 mg daily for 1 week)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fenoprofen (2400 mg daily for 1 week)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30286628

Group type: EXPERIMENTAL
Intervention: Invagination of the hernial sac (Group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Excision of the hernial sac (Group B)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 70
Study: 27780336

Group type: EXPERIMENTAL
Intervention: Life Goals Collaborative Care (n = 146)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Usual Care (n = 147)
Number of subjects: 293
Study: 26032729

Group type: EXPERIMENTAL
Intervention: Tailored delirium prevention protocol applied daily for the first 7 days of ICU hospitalization
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Tailored delirium prevention protocol
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study: 23179146

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 423

Group type: COMPARATOR
Intervention: Placebo or no intervention
Number of subjects: 423
Study: 22055098

Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil
Number of subjects: 206